In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species

Clinical Microbiology and Infection

Volumn 7, Issue 1, 2000, Pages 11-16

  Moore, C B ^a   Oakley, K L ^a,d   Denning, D W ^a,b,c  

^a HOPE HOSPITAL   (United Kingdom)

^b NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d HEALTH AND SAFETY LABORATORY   (United Kingdom)

Author keywords

Amphotericin B; Candida; Echinocandin; Fluconazole; Flucytosine; LY303366; Susceptibility; Tolerance

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIBIOTIC AGENT; FLUCONAZOLE; FLUCYTOSINE; GLUCOSE; RPMI 1640; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GUILLIERMONDII; CANDIDA PARAPSILOSIS; CONTROLLED STUDY; CULTURE MEDIUM; DILUTION; DRUG RESISTANCE; DRUG TOLERANCE; FUNGUS GROWTH; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY;

CANDIDA; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; FUNGI; PICHIA GUILLIERMONDII;

EID: 0035239765     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2001.00158.x     Document Type: Article

References (37)

1. High prevalence of antifungal resistance in Candida spp. from patients with AIDS
2. Azole resistance in Candida
3. Echinocandins and pneumocandins - A new antifungal class with a novel mode of action
4. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates
5. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents
6. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
7. In vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients
8. In vitro activity of a new semisynthetic echinocandin, LY303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species
9. LY303366, activity in a murine systemic candidiasis model
10. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits
11. Efficacy of LY303366 against amphotericin B-susceptible and - Resistant Aspergillus fumigatus in a murine model of invasive aspergillosis
12. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp
13. Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo
14. LY303366, activity against systemic aspergillosis and histoplasmosis in murine models
15. Detection of amphotericin B-resistant Candida isolates in a broth-based system
16. Quality control guidelines for National Committe for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine
17. Evaluation of endpoints for antifungal susceptibility determination with LY303366
18. Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii
19. Fluconazole-resistant Candida parapsilosis fungemia in a patient with AIDS
20. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance
21. Antifungal susceptibility testing of isolates from a randomized multicentre trial of fluconazole versus amphotericin B as treatment of non neutropenic patients with candidaemia
22. Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata and Candida krusei
23. Origin of differences in susceptibility of Candida krusei to azole antifungal agents
24. Correlation between in vitro and in vivo activity of antifungal agents against Candida species
25. Molecular taxonomy of Candida inconspicua
26. Candida incospicua, a fluconazole-resistant pathogen in patients infected with human immunodeficiency virus
27. In vitro susceptibilities of sucrose negative Candida tropicalis. Candida lusitaniae, and Candida norvegensis to amphotericin B, 5-fluorocytosine, miconazole and ketoconazole
28. Development of resistance to amphotericin B in Candida lusitaniae infecting a human
29. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period
30. An analysis of the trends in the use of antifungal drugs and fungal isolates in a UK University hospital
31. Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)
32. Amphotericin B-resistant yeast infection in severely immunocompromised patients
33. LY303366 single dose pharmacokinetics and safety in healthy male volunteers
34. Amphotericin B tolerance: A characteristic of Candida parapsilosis not shared by other Candida species
35. Growth medium effect on the antifungal activity of LY 303366
36. LY303366 exhibits rapid and potent fungicidal activity in flow cytometric assays of yeast viability